Mental Health
Drug Receives FDA's Breakthrough Therapy Designation for Treating Individuals with Schizophrenia
Drug Receives FDA's Breakthrough Therapy Designation for Treating Individuals with Schizophrenia
The designation is intended to expedite the development and review of drugs for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on one or more clinically significant endpoints.
Read More >>
Study Examines Benzodiazepines with Antipsychotics for Aggression
Medication for Aggression: What Works and Where?
Bipolar Disorder: Opportunity for Pharmacists to Improve Adherence and Health Outcomes
Pharmacists Can Help Prevent Suicides
Comparable Efficacy of Generic and Brand-Name Drugs for Chronic Conditions Shown in Study
Study: Certain ADHD Medications May Increase the Risk of Psychosis
Carefully Assess Bleeding Risk in Patients on Antidepressants
View more articles >>
Clinical Trials
Bipolar Disorder and Oxidative Stress Injury Mechanism - Clinical Big Data Analysis Based on Machine Learning
EMDR in Adolescents With Bipolar Disorder and History of Trauma
Dietary Intervention for Bipolar Disorder
High Intensity Interval Training in Severe Mental Illness
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
Multimedia: Videos
Schizophrenia: Quality of Care & Relapse Prevention
Schizophrenia: Quality of Care & Relapse Prevention
Emerging Therapies & Strategies in Schizophrenia
Emerging Therapies & Strategies in Schizophrenia
Improving Resistance to Use LAI Therapy in Schizophrenia
Improving Resistance to Use LAI Therapy in Schizophrenia
LAI Antipsychotics in Schizophrenia: Clinician's Role
LAI Antipsychotics in Schizophrenia: Clinician's Role